Edge Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Edge Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16	Closed	-$2K	–	274
2021 Q4	$2K	Hold	16	–	–	﹤0.01%	424
2021 Q3	$2K	Buy	+16	New	+$2.42K	﹤0.01%	437
2014 Q4	–	Sell	-500	Closed	-$80K	–	419
2014 Q3	$80K	Hold	500	–	–	0.03%	151
2014 Q2	$73K	Hold	500	–	–	0.03%	158
2014 Q1	$69K	Buy	+500	New	+$75.3K	0.03%	154

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Edge Wealth Management's JAZZ Position: Q1 2022 in Review

Edge Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 16 shares — an estimated $2K sold.

Edge Wealth Management first reported a position in JAZZ in Q1 2014 and held it in 5 quarters. The position peaked at $80K in Q3 2014. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Edge Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Edge Wealth Management sold 16 Jazz Pharmaceuticals shares in Q1 2022, an estimated $2K.
Edge Wealth Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Edge Wealth Management's Jazz Pharmaceuticals position peaked at $80K in Q3 2014.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.